W ith the arrival of imatinib (Gleevec) a decade ago, chronic myelogenous leukemia (CML) turned into a chronic disease. Clinicians hailed its estimated 85% success rate in the rare but deadly cancer as a triumph for the new field of targeted therapeutics. Last year, Novartis to pursue development of imatinib and ran its pivotal clinical trials, received the prestigious Lasker-DeBakey Award for ...

BACKGROUND With the rate of kidney disease on the rise, and a serious imbalance between the number of patients requiring a kidney transplant and the number of available donor kidneys, it is becoming increasingly important to develop alternative strategies to restore organ function to diminish the need for human donors. SUMMARY We review the current progress and future directions of a subset o...